Citadel Advisors LLC decreased its stake in shares of Galapagos NV (NASDAQ:GLPG) by 79.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,870 shares of the biotechnology company’s stock after selling 11,309 shares during the quarter. Citadel Advisors LLC’s holdings in Galapagos were worth $269,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in shares of Galapagos by 254.3% in the 2nd quarter. Royal Bank of Canada now owns 4,170 shares of the biotechnology company’s stock valued at $319,000 after acquiring an additional 2,993 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Galapagos in the 4th quarter valued at about $3,652,000. Bank of Montreal Can increased its holdings in shares of Galapagos by 84.1% in the 4th quarter. Bank of Montreal Can now owns 5,205 shares of the biotechnology company’s stock valued at $488,000 after acquiring an additional 2,377 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Galapagos in the 3rd quarter valued at about $3,072,000. Finally, Northern Trust Corp increased its holdings in shares of Galapagos by 2.9% in the 2nd quarter. Northern Trust Corp now owns 18,480 shares of the biotechnology company’s stock valued at $1,414,000 after acquiring an additional 524 shares during the last quarter. Institutional investors and hedge funds own 19.51% of the company’s stock.
A number of research firms have recently commented on GLPG. ValuEngine upgraded Galapagos from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub upgraded Galapagos from a “hold” rating to a “buy” rating in a research note on Wednesday, January 31st. BTIG Research restated a “buy” rating and set a $118.00 price target on shares of Galapagos in a research note on Thursday, February 8th. Finally, Zacks Investment Research downgraded Galapagos from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. Galapagos presently has an average rating of “Hold” and a consensus target price of $111.00.
Galapagos NV (GLPG) opened at $103.91 on Thursday. The stock has a market capitalization of $5,260.00, a P/E ratio of -38.86 and a beta of 0.99. Galapagos NV has a 12 month low of $72.90 and a 12 month high of $121.09.
COPYRIGHT VIOLATION NOTICE: “Citadel Advisors LLC Sells 11,309 Shares of Galapagos NV (GLPG)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/15/citadel-advisors-llc-sells-11309-shares-of-galapagos-nv-glpg.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.